

ABOUT DAVOS LIFE SCIENCE

- 2004** Davos Life Science was founded in Singapore as one of the world's largest manufacturers of Tocotrienols.
- 2005-2010** Kuala Lumpur Kepong Berhad (KLK) begins investing in Davos Life Science. KLK is a leading international plantations group listed on Main Market of Bursa Malaysia Securities Berhad with a market capitalisation of approximately RM24.9 (USD6) billion at the end of September 2019.
- 2010** Davos Life Science is fully incorporated into the KLK OLEO Group of Companies. KLK OLEO is a leading oleochemicals manufacturer with 15 manufacturing facilities worldwide supplying to over 120 countries.
- 2012** Manufacturing facilities were expanded and relocated to Westport, Malaysia.
- 2018** We diversify our phytonutrient offerings to include natural mixed carotenes.
- TODAY** Davos Life Science is one of the leading market players producing high quality Tocotrienols and Mixed Carotenes.

**Derived From Nature
Driven By Science**

KLK OLEO

DavosLife E3 Tocotrienols

Tocotrienols are potent antioxidants and anti-inflammatory agents with wide-reaching, clinically proven health benefits.

Vitamin E



Heart



Brain



Liver



Bone



Skin



For medical professional use.

Evidence-based Benefits

Heart Health

- ✓ Tocotrienols have unique cholesterol lowering properties that are not shared by α -Tocopherol^{1,4}.
- ✓ Supplementation with Tocotrienols improved plasma total cholesterol, triglycerides, and high-density lipoproteins (HDL) when compared to placebo^{2,3}.

Brain Health

- ✓ α -Tocotrienol is the most potent neuroprotective Vitamin E isomer⁵.
- ✓ It is more effective than α -Tocopherol in preventing glutamate-induced brain injury and death¹.

Liver Health

- ✓ Tocotrienols are clinically proven to improve liver health biomarkers and liver pathophysiology in non-alcoholic fatty liver disease patients⁶.

Bone Health

- ✓ Tocotrienols improve bone density by increasing osteoblast number, mineral deposition, bone formation activity, and decreasing osteoclast number, erosion on bone, and bone resorption activity¹.
- ✓ In contrast, the bone protecting benefits of α -Tocopherol are inconsistent and contradictory⁷.

Skin Health

- ✓ Tocotrienols have skin lightening properties⁸, which is not seen in α -Tocopherol.
- ✓ Clinical trials have confirmed Tocotrienols' efficiency in reducing skin redness and pigmentation following UV irradiation⁹.
- ✓ Tocotrienols stimulate collagen synthesis in the skin¹⁰.





























For medical professional use.

DavosLife E3


DavosLife E3 is a line of naturally derived Tocotrienol products from Oil Palm (*Elaeis guineensis*).

- ✓ Contains the full spectrum of Tocotrienol isomers (α -, β -, γ -, δ -) and α -Tocopherol.
- ✓ Complies to major international regulatory standards on Persistent Organic Pollutants (POPs) and other contaminants in food and health supplements.
- ✓ Dosage recommendations: 50 - 100 mg Tocotrienols daily for overall wellness.

Applications

DavosLife E3 Products	Vitamin E Content	Hard Capsules	Softgel Capsules	Cosmetics	Sachets	Aqueous Liquids	Dry Food Products	Oil-based Food Products
Tocotrienols Liquid								
DVL 95	95%							
DVL 84	84%							
DVL 658i	65%							
DVL 50	50%							
DVL 503	50%							
Bio-Enhanced 20	20%							
Tocotrienols Powder								
DVP 30-WD	30%							

Accreditations



ECOCERT COSMOS is applicable for DAVOSLIFE E3 DVL 50, DVL 503, and DVL 95.

DavosLife E3 Bio-Enhanced 20 formulation is protected by patents in the United States of America, Australia, India, Japan, New Zealand, and Indonesia. Patent approvals in other countries are still pending. See www.klkoleo.com/davoslife/patents for granted and pending patents in all countries.

References:

1. Peh et al. (2016). *Pharmacology & Therapeutics*, 162: 152 – 169.
2. Zaiden et al. (2010). *Journal of Atherosclerosis and Thrombosis*, 17(10): 1019 – 1032.
3. Daud et al. (2013). *Vasc. Health Risk Manag.*, 9: 747 – 761.
4. Wade et al. (2013). *Atherosclerosis*, 226: 392 – 397.
5. Sen et al. (2010). *J Am Coll Nutr.*, 29 (3): 314S – 323S.
6. Perves et al. (2018). *Turk J. Gastroenterol.*, 29: 170 – 6.
7. Chin and Ima-Nirwana (2014). *Nutrients*, 6: 1424 – 1441.
8. Yap et al. (2010). *Pigment Cell Melanoma Res.*, 23(5): 688-692.
9. Yap, WN. (2017). *J. Cosmet. Dermatol.*, : 1-11.
10. Makpol et al. (2011). *Arch Med. Sci.*, 889 - 895

www.klkoleo.com/DavosLife